Literature DB >> 23329306

Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.

Bing Bai1, Hui-Qiang Huang, Qi-Chun Cai, Wei Fan, Xiao-Xiao Wang, Xu Zhang, Ze-Xiao Lin, Yan Gao, Yun-Fei Xia, Ying Guo, Qing-Qing Cai, Wen-Qi Jiang, Tong-Yu Lin.   

Abstract

The role of (18)Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in extranodal natural killer/T-cell lymphoma (ENKL) is not well established. This study aimed to investigate the prognostic role of the pretreatment maximum standardized uptake value (SUV(max)) on PET/CT in patients with newly diagnosed ENKL. Among 364 consecutive patients with newly diagnosed ENKL, 81 patients were included and reviewed. The impact of SUV(max) on survival and the relationship between SUV(max) and other clinicopathological parameters were analyzed. The median SUV(max) was 14.6 (range 2.0-45.4). The optimal cutoff value of SUV(max) to predict overall survival (OS) was 15. Patients with high SUV(max) (SUVmax >15) were associated with bulky disease (P < 0.001), local invasion (P = 0.030), high score of Korean Prognostic Index (KPI, P = 0.046), resistance to primary treatment (P = 0.014), poor OS (P < 0.001), and unfavorable progression-free survival (P < 0.001). With a median follow-up of 25.0 months, the median OS was 63.0 months (range 2.0-99.0 months). Multivariate analyses revealed the following independent prognostic factors for OS: age >60 years (P = 0.001), stage III-IV (P = 0.023), SUV(max) >15 (P = 0.020), and bulky disease (>5 cm) (P = 0.002). By using the SUV(max), patients in most subgroups stratified by the KPI or the International Prognostic Index (IPI) were further discriminated in OS with significant statistical difference. Our results suggest the pretreatment SUV(max) is predictive of prognosis in patients with newly diagnosed ENKL. The SUV(max) may provide additional prognostic information for IPI and KPI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23329306     DOI: 10.1007/s12032-012-0339-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  40 in total

1.  Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients.

Authors:  Wing-Yan Au; Annie Pang; Carolyn Choy; Chor-Sang Chim; Yok-Lam Kwong
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

2.  Role of positron emission tomography in lymphoma.

Authors:  Malik E Juweid; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

3.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

4.  Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.

Authors:  Jeeyun Lee; Yeon Hee Park; Won Seog Kim; Seung-Sook Lee; Baek-Yeol Ryoo; Sung Hyun Yang; Keon Woo Park; Jung Hoon Kang; Joon Oh Park; Se Hoon Lee; Kihyun Kim; Chul Won Jung; Young Suk Park; Young-Hyuck Im; Won Ki Kang; Mark H Lee; Young H Ko; Yong Chan Ahn; Keunchil Park
Journal:  Eur J Cancer       Date:  2005-07       Impact factor: 9.162

5.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index.

Authors:  Chor-Sang Chim; Shing-Yan Ma; Wing-Yan Au; Carolyn Choy; Albert K W Lie; Raymond Liang; Chun-Chung Yau; Yok-Lam Kwong
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

7.  Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis.

Authors:  Soon Thye Lim; Siew Wan Hee; Richard Quek; Lay Cheng Lim; Swee Peng Yap; Er-Li Loong; Ivy Sng; Leonard Hwan-Cheong Tan; Mei-Kim Ang; Joanne Ngeow; Chee-Kian Tham; Lynette Ngo; Min Han Tan; Miriam Tao
Journal:  Eur J Haematol       Date:  2007-11-20       Impact factor: 2.997

8.  The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.

Authors:  Dimitrios Karantanis; Rathan M Subramaniam; Patrick J Peller; Val J Lowe; Jolanta M Durski; Douglas A Collins; Evangelos Georgiou; Stephen M Ansell; Gregory A Wiseman
Journal:  Clin Lymphoma Myeloma       Date:  2008-04

9.  Nation-wide study of lethal mid-line granuloma in Japan: frequencies of wegener's granulomatosis, polymorphic reticulosis, malignant lymphoma and other related conditions.

Authors:  K Aozasa; M Ohsawa; K Tajima; R Sasaki; H Maeda; T Matsunaga; I Friedmann
Journal:  Int J Cancer       Date:  1989-07-15       Impact factor: 7.396

10.  Nasal-type NK/T cell lymphoma: clinical features and treatment outcome.

Authors:  J Lee; W S Kim; Y H Park; S H Park; K W Park; J H Kang; S S Lee; S I Lee; S-H Lee; K Kim; C W Jung; Y C Ahn; Y H Ko; K Park
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640

View more
  9 in total

1.  Management of advanced NK/T-cell lymphoma.

Authors:  Eric Tse; Yok-Lam Kwong
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

2.  Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis.

Authors:  Sheng-Ming Deng; Wei Zhang; Bin Zhang; Yin-Yin Chen; Ji-Hui Li; Yi-Wei Wu
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

3.  Prognostic value of baseline, interim and end-of-treatment 18F-FDG PET/CT parameters in extranodal natural killer/T-cell lymphoma: A meta-analysis.

Authors:  Hongxi Wang; Guohua Shen; Chong Jiang; Li Li; Futao Cui; Rong Tian
Journal:  PLoS One       Date:  2018-03-20       Impact factor: 3.240

Review 4.  Positron emission tomography/computed tomography in the diagnosis, staging, and prognostic evaluation of natural killer/T-cell lymphoma.

Authors:  Jian-Jun Ding; Ya-Lian Chen; Shui-Hong Zhou; Kui Zhao
Journal:  J Int Med Res       Date:  2018-10-17       Impact factor: 1.671

5.  Characteristics, Prognostic Factors, and Survival of Patients with NK/T-Cell Lymphoma of Non-upper Aerodigestive Tract: A 17-Year Single-Center Experience.

Authors:  Ze-Long Liu; Xi-Wen Bi; Xue-Wen Zhang; De-Xin Lei; Pan-Pan Liu; Hang Yang; Yan Gao; Yuan-Xue Jiang; Wen-Qi Jiang; Yi Xia
Journal:  Cancer Res Treat       Date:  2019-04-01       Impact factor: 4.679

6.  Nomograms based on SUVmax of 18F-FDG PET/CT and clinical parameters for predicting progression-free and overall survival in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.

Authors:  Hongyan Li; Guozhu Shao; Yajing Zhang; Xiaomin Chen; Chengcheng Du; Kun Wang; Zairong Gao
Journal:  Cancer Imaging       Date:  2021-01-08       Impact factor: 3.909

7.  Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings.

Authors:  Yu Kong; Lili Qu; Yuekai Li; Dai Liu; Xuemin Lv; Jiankui Han
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

8.  Weakly supervised deep learning for determining the prognostic value of 18F-FDG PET/CT in extranodal natural killer/T cell lymphoma, nasal type.

Authors:  Rui Guo; Xiaobin Hu; Haoming Song; Pengpeng Xu; Haoping Xu; Axel Rominger; Xiaozhu Lin; Bjoern Menze; Biao Li; Kuangyu Shi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-20       Impact factor: 9.236

9.  Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer/T-cell lymphoma.

Authors:  Xianwu Xia; Yaqi Wang; Jianjun Yuan; Wenjie Sun; Jinjin Jiang; Chang Liu; Qunling Zhang; Xuejun Ma
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.